We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
JORVEZA Dr Falk Pharma Australia Pty Ltd
Product name
JORVEZA
Sponsor
Accepted date
May-2025
Active ingredients
budesonide
Proposed indication
JORVEZA (budesonide) is for the treatment of eosinophilic oesophagitis, a condition where high levels of eosinophils (a type of white blood cell) cause chronic inflammation in the oesophagus.
Application type
C (new indication)
Publication date
May-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.